Heart Failure With Reduced Ejection Fraction Caused by Osimertinib in a Patient With Lung Cancer: A Case Report and Literature Review

Osimertinib is widely used for the treatment of advanced lung cancers harboring epidermal growth factor receptor (EGFR) mutations. Because of its inhibitory activity on the human epidermal growth factor receptor 2 pathway, osimertinib-induced cardiotoxicity is concerning. Large-scale international c...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuzumi, Shinichi, Matsuda, Masahiro, Nagao, Genta, Kakimoto, Tomoo, Minematsu, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441008/
https://www.ncbi.nlm.nih.gov/pubmed/36081968
http://dx.doi.org/10.7759/cureus.27694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441008/
https://www.ncbi.nlm.nih.gov/pubmed/36081968
http://dx.doi.org/10.7759/cureus.27694

Ejemplares similares